| Topamax Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Topamax 25 mg | tablet | oral | 1.0 each | OTC |
| Topamax 100 mg | tablet | oral | 1.0 each | OTC |
| Topamax 200 mg | tablet | oral | 1.0 each | OTC |
| Topamax 50 mg | tablet | oral | 1.0 each | OTC |
Posted by m4johnso 3 days ago
I just got off topamax after being on 800 mg/day for over a year. Unlike most of you, I used it to treat seizures. Because ...
Posted by neuro58 7 days ago
I was only on 25 mg of Topamax for two months and had to stop due to the terrible side effects of mouth numbness, taste avers...
Posted by twinmom1967 7 days ago
Oh My God! Reading all of these is like reading about myself. In the last 8 weeks I have gone from being a somewhat normal p...
Study Finds IONSYS™, A New Needle-Free System For Management Of ... - Medical News Today (press release)
... CONCERTA® (ADHD), EPREX® (anaemia), SPORANOX® (fungal infections), VELCADE® (multiple myeloma), PARIET® (gastroenterology), TOPAMAX® (epilepsy), ...
Mon Mar 10 03:09:06 -0400 2008
Study finds IONSYS (TM), a New Needle-Free System for Management ... - PR Newswire UK (press release)
... SPORANOX(R) (fungal infections), VELCADE(R) (multiple myeloma), PARIET(R) (gastroenterology), TOPAMAX(R) (epilepsy), REMINYL(R) (Alzheimer's disease), ...
Tue Mar 04 01:06:57 -0500 2008
Benefiting From 2008's Generic Drugs - Motley Fool
Other blockbusters losing their patent protection in 2008 include Johnson & Johnson's (NYSE: JNJ) Topamax, which Barr Labs and Mylan (NYSE: MYL) are set to ...
Thu Feb 28 14:45:19 -0500 2008
topiramate - A sulfamate-substituted monosaccharide with anticonvulsant property. Although the mechanism of action has not been fully elucidated, topiramate antagonizes kainate/AMPA subtype of the glutamate receptors, which are ligand-activated cation channels that mediate the fast component of excitatory postsynaptic currents in neurons of the central nervous system. This antagonistic action results in stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing propagation of synaptic impulses, thereby impedes seizure occurrences. In addition, this agent augments gamma-aminobenzoic acid (GABA) activity and thereby attenuating GABAnergic inhibitory transmission.